A total of 5–10% of thyroid cancer patients have progressive disease, refractory to conventional therapies (candidates for clinical trials). The molecular pathogenesis of thyroid cancer has been ...

The hypothalamic–pituitary–thyroid axis plays a crucial role in the pathogenesis, diagnosis, risk stratification, effectiveness of radioiodine therapy, and treatment response evaluation in epithelial ...

The following is a summary of “Underutilized treatments for patients with refractory cancer pain: A qualitative study assessing the use of intrathecal drug delivery devices in the United Kingdom ...

Eisai’s Lenvima was first approved by the FDA in February 2015 for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).

Nuclear medicine therapy involves delivering radiation-emitting drugs directly inside the body to treat refractory cancers ... five-year survival rate for thyroid cancer that has spread to ...

Although able to target specific oncogene mutations associated with thyroid cancer, effective responses have not yet been associated with a specific oncogenic profile. Indeed, effective responses ...